Breaking News

U.S. Court Vacates Modified Consent Decree Imposed on Xellia’s Cleveland Facility

Since entering the Decree in 2016, Xellia’s site has been regularly inspected by the FDA to determine compliance with rules and regulations.

Author Image

By: Charlie Sternberg

Associate Editor

The U.S. Court has vacated the Modified Consent Decree imposed on Xellia Pharmaceuticals’ Cleveland, Ohio facility in 2016.   The original Consent Decree for the manufacturing site was entered into by the U.S. Food and Drug Administration (FDA) and the previous site owner, Ben Venue Laboratories Inc. (BVL) in January 2013. Because Consent Decrees are site-specific and do not relate to the owner, when Xellia acquired the site in November 2015, the Company entered an associated Modified Consent ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters